🧬Insights about the company winning against cancer 📈The potential to save millions & make millions 🤝Unaffiliated with Alpha Tau Medical
Joined March 2025
- Tweets817
- Following113
- Followers609
- Likes1.6K
Alpha Tau (NASDAQ: $DRTS) Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
globenewswire.com/news-relea…
Congrats Dr. @joshuapalmermd! Can’t wait to hear your presentation at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting.
Alpha Tau Insight retweeted
Alpha DaRT in focus at Guy Natan's Investment Generation conference.
CEO Uzi Sofer shared what it truly takes to bring a new cancer treatment modality from idea to patient—building the global capabilities to deliver individualized care.
Alpha Tau Insight retweeted
$DRTS CEO Uzi Sofer getting interviewed on Channel 10, The Israeli Financial Channel, amid the upcoming addition of the stock into the TA-90 and TA-125 indexes
Welcome to Guy Natan's Investment Generation Conference where $DRTS will be featured and presenting
Follow this thread and @AlphaTauInsight for on site reporting🧵⬇️
$DRTS CEO Uzi Sofer presenting on the main stage at Guy Natan's Investment Generation Conference
$DRTS CEO Uzi Sofer getting interviewed on Channel 10, The Israeli Financial Channel, amid the upcoming addition of the stock into the TA-90 and TA-125 indexes
Alpha Tau Insight retweeted
$DRTS CEO Uzi Sofer presenting on the main stage at Guy Natan's Investment Generation Conference
Alpha Tau Insight will be reporting on site.
Follow for updates.
$DRTS
Bringing new cancer therapy to patients takes more than tech—it needs evidence and global infrastructure.
Tomorrow, @AlphaTauMedical CEO Uzi Sofer speaks at the Investment Generation conference.
🗓 Oct 15 | 12:30 PM 📍 Cinema City, Rishon LeZion
Alpha Tau (NASDAQ: $DRTS & TASE: דרטס) is expected to join the TA-90 and TA-125 indexes this coming November, per reports
The company that has been dual listed and is trading on the TASE since August 13 is quickly making a name for itself in the growing local market
Alpha Tau Insight retweeted
Excellent observation and insight found on LinkedIn regarding Alpha Tau Medical and Alpha Dart
$DRTS
Celebrating 600 Followers for @AlphaTauInsight 🎉
May we celebrate many more Alpha Tau Medical achievements together, as the company continues to make a real difference worldwide, and we join in the mission to save millions (and make millions).
“This is just the little engine that could, I’m expecting $20 and $25 here”
JR Romero @PicardTrades loves the $DRTS setup and trend, as he shared today on @t3live:
Alpha Tau Insight retweeted
Tks “Later, an additional advanced treatment using different insertion pathways was also performed at Hadassah. For an Israeli company, seeing the technology we developed reach the treatment of such a complex brain tumor, here in Jerusalem, is a moment of special significance.”
Alpha Tau Insight retweeted
This is fascinating. If I recall correctly, the Hadassah hospital was waiting and preparing and didn't get a patient for Alpha Tau's rGBM platform and now they have two.
This could explain why Uzi's Rosh HaShannah (New Year) letter starts with rGBM.
It could explain why Barclays raised $DRTS price target to $30 citing rGBM results.
It could explain @Anders_Research leading with rGBM and claiming a $10B market cap.
There are oncologists out there, beyond Hadassah in Israel, that know full well whether the procedure is effective or not. If any of them spoke with Barclays or Anders, we know why they're leading with rGBM and not PDAC Pancreatic or the combination therapy with Merck's Keytruda, despite how massive both those opportunties may be.
I am becoming more bullish with each passing day when it comes to Alpha Tau Medical. May this coming year be a very, very bad year for solid tumors because of the hard work Alpha Tau has done.
🚨BREAKING: $DRTS Has Treated Two GBM Patients In Israel
In an open letter to Alpha Tau employees, the CEO has shared that a second GBM patient was treated in Israel, after the first was announced a couple months ago
These patients are in addition to the REGAIN trial in the US
After Barclays set a price target of $30, and the stock closed over $15 for the first time on Friday, while NASDAQ is closed for Laber Day, $DRTS was trading on the TASE today and closed as high as the equivalent of $15.89
